Trial Profile
Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 20 Sep 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2025.
- 20 Sep 2021 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2022.
- 10 Aug 2020 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.